In short
MRT1802 is an investigational mRNA vaccine being studied for the treatment of moderate to severe acne. One authorised Phase 1/2 trial (NCT06316297) plans to enrol 549 adults to assess the vaccine's safety, efficacy and immunogenicity. The trial is designed with sentinel cohorts for safety and main cohorts for efficacy, followed by a long-term extension.
Key points
- MRT1802 is an mRNA vaccine candidate for moderate to severe acne.
- The only registered trial is a Phase 1/2 study with 549 planned participants.
- The trial is currently authorised but not yet recruiting.
- It measures safety (adverse events) and efficacy (reduction in acne lesions).
- The vaccine is given by intramuscular injection.
- The study includes a long-term extension to assess lasting safety.
What is MRT1802?
MRT1802 is an investigational mRNA vaccine being developed for the treatment of acne. It is not an authorised medicine; it is currently being evaluated in clinical research. The substance is given as an intramuscular injection and is being studied in adults with moderate to severe acne.
How does MRT1802 work?
The trial record does not describe the mechanism of action of MRT1802 in detail. As an mRNA vaccine, it is expected to deliver genetic instructions to cells, but the specific molecular target in acne is not stated in the available registry data.
Which conditions is MRT1802 being studied for?
- Acne — a common skin condition involving inflamed and non-inflamed lesions on the face. The trial focuses on moderate to severe forms of acne in adults.
How is MRT1802 given?
MRT1802 is administered as an intramuscular injection. The trial also uses a diluent of 0.9% sodium chloride solution as part of the preparation.
What do the clinical trials show?
One clinical trial of MRT1802 is registered. It is a Phase 1/2 interventional study with a planned enrolment of 549 participants and is currently authorised but not yet recruiting. The study is divided into sentinel cohorts and main cohorts. The sentinel cohorts evaluate safety, while the main cohorts assess efficacy by measuring the percentage change from baseline in inflammatory and non-inflammatory acne lesions on the face. A long-term extension will assess safety over a longer period.
The primary outcomes include the number of participants with solicited and unsolicited adverse events, serious adverse events, adverse events of special interest, and out-of-range biological test results. Efficacy outcomes focus on the percentage reduction in acne lesion counts.
Who can take part in the trial?
The trial enrols adults with moderate to severe acne. Further eligibility criteria are not detailed in the registry record.
What side effects are known?
No side effects of MRT1802 have been reported in the available data. The trial is designed to collect information on solicited injection site reactions, systemic reactions, unsolicited adverse events, serious adverse events and adverse events of special interest.